Overview

Double-Blind, Randomized, Single Dose Escalation Safety Study of Intraarticular Bone Morphogenic Protein (38A BMP-7) in Subjects With Osteoarthritis (OA) of the Knee

Status:
Completed
Trial end date:
2011-10-01
Target enrollment:
Participant gender:
Summary
The objective of the study is to determine the safety and tolerability of two different formulations of BMP-7 for the treatment of osteoarthritis of the knee.
Phase:
Phase 1
Details
Lead Sponsor:
Stryker Biotech